FDA to Issue New Commissioner’s National Priority Vouchers to Companies Supporting U.S. National Interests | FDA
The .gov means it’s official.Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. FDA NEWS RELEASE More Press Announcements The U.S. Food and Drug Administration today announced its Commissioner’s National Priority Voucher (CNPV) program to enhance the health interests of Americans. The new voucher may be redeemed by drug developers to participate in a novel priority program by the FDA that shortens its review time from approximately 10-12 months to 1-2 months following a sponsor’s final drug application submission. The new CNPV process convenes experts from FDA offices for a team-based review rather than using the standard review system of a drug application being sent to numerous FDA offices. Clinical information will be reviewed by a
More Press Announcements For Immediate Release: June 17, 2025 The U.S. Food and Drug Administration today announced its Commissioner’s National Priority Voucher (CNPV) program to enhance the health interests of Americans. The new voucher may be redeemed by drug developers to participate in a novel priority program by the FDA that shortens its review time from approximately 10-12 months to 1-2 months following a sponsor’s final drug application submission. The new CNPV process convenes experts from FDA offices for a team-based review rather than using the standard review system of a drug applic
related reading
- FDA Announces Major Steps to Implement Real-Time Clinical Trials | FDAfda.gov
- America Must Address Early Clinical Developmentfda.gov
- Product-Specific Regulatory Pathways to Approve Generic Drugs: The Need for Follow-up Studies to Ensure Safety and Effectiveness - PubMedpubmed.ncbi.nlm.nih.gov
- FDA Launches Framework for Accelerating Development of Individualized Therapies for Ultra-Rare Diseases | FDAfda.gov
- White House proposes new rules giving political appointees final approval on research grantsyahoo.com
- Federal Register :: National Electric Vehicle Infrastructure Standards and Requirementsfederalregister.gov
- Press Release: Sanofi’s venglustat accepted for priority review in the US to treat type 3 Gaucher diseasesanofi.com
- Federal Register :: Platform Technology Designation Program; Draft Guidance for Industry; Availability; Agency Information Collection Activities; Proposed Collection; Comment Requestfederalregister.gov
- Advanced Research Projects Agency for Health - Wikipediaen.wikipedia.org
- Guidance for Industryfda.gov
- Why the FDA Is Slow to Remove Drugspress.asimov.com
- Canadian and US drug approval times and safety considerations - PubMedpubmed.ncbi.nlm.nih.gov